Sionna Therapeutics (NASDAQ:SION) Director Peter Thompson Sells 94,583 Shares

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 94,583 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82. Following the sale, the director owned 3,610,376 shares in the company, valued at $160,806,147.04. This represents a 2.55% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Sionna Therapeutics Trading Down 1.1%

NASDAQ SION traded down $0.49 on Wednesday, hitting $43.79. 179,798 shares of the company’s stock were exchanged, compared to its average volume of 224,671. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $45.00. The stock has a 50-day moving average of $33.61 and a 200-day moving average of $23.82. The stock has a market cap of $1.95 billion and a price-to-earnings ratio of -8.99.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. bought a new stake in Sionna Therapeutics in the third quarter worth about $30,000. BNP Paribas Financial Markets purchased a new stake in Sionna Therapeutics in the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of Sionna Therapeutics during the 2nd quarter valued at $45,000. Virtus Investment Advisers LLC purchased a new stake in Sionna Therapeutics in the 2nd quarter worth about $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Sionna Therapeutics in the 2nd quarter valued at about $117,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on SION. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Tuesday. Wall Street Zen lowered Sionna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Jones Trading assumed coverage on Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 price objective for the company. Royal Bank Of Canada began coverage on shares of Sionna Therapeutics in a research report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 target price for the company. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Sionna Therapeutics in a research report on Wednesday, November 5th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.00.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.